Why the study?
Does carvedilol improve symptoms, exercise, ejection fraction, and oxidative stress compared to metoprolol in patients with heart failure?
Does carvedilol improve symptoms, exercise, ejection fraction, and oxidative stress compared to metoprolol in patients with heart failure?
Carvedilol and metoprolol provide similar benefits on symptoms, exercise capacity, ejection fraction, and oxidative stress over 6 months in patients with heart failure.
Either agent may be selected by tolerability or cost; confirms beta-blocker class equivalence on symptoms, capacity, and EF in HF.
Carvedilol and metoprolol showed parallel beneficial effects in the measured parameters over 6 months, with no relevant between-group differences in this heart failure population.
No takes yet. Share an insight, caveat, or question.
Kukin et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: